Egis World
Egis' products are sold to 100 countries.

Egis keeps growing in OTC markets via acquisition

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets.


Egis expands gynecological and dermatological portfolio in Russia

Egis Pharmaceuticals expands portfolio thus improves Russian people’s access to its high quality, EU manufactured therapies.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox